Saturday 17 October 2026
Export OWLT’s income statement to Excel — free account
Owlet, Inc.
OWLT Healthcare Medical Devices
In the quarter to June 2026, revenue grew 29.9%, EPS grew 97.9%, free cash flow grew 55.7% and total debt fell 16.9%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
4.14
0.30
−6.76%
Follow OWLT
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | 134.96 | 34.02 | 7.52 | 2.52 | 3.20 | 2.75 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | — | — | 143.92 | 161.84 | 74.90 | 9.69 | 7.50 | 16.94 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | — | 3 | 200 | 106 | 76 | 85 | 114 | ||||
| Revenue/emp, $m | — | — | — | — | 25.13 | 0.38 | 0.65 | 0.71 | 0.92 | 0.93 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | 75 | 76 | 69 | 54 | 78 | 106 | ||||
| Gross margin, % | — | — | — | — | 47.58 | 46.23 | 33.69 | 41.82 | 50.36 | 50.64 | |||||
| EBT | — | — | — | — | (11) | (72) | (79) | (33) | (12) | (40) | |||||
| EBT margin, % | — | — | — | — | (13.93) | (94.50) | (114.60) | (60.90) | (15.99) | (37.51) | |||||
| Net income | — | 0 | — | — | (11) | (72) | (79) | (33) | (13) | (40) | |||||
| Depreciation | — | — | — | — | 1 | 1 | 3 | 2 | 4 | 3 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | — | — | 48.10 | 16.80 | 8.70 | 6.53 | 7.13 | 5.84 | ||||
| Earnings | — | — | — | — | (6.71) | (15.83) | (9.94) | (4.53) | (1.57) | (2.31) | |||||
| Cash flow | — | — | — | — | (0.08) | (8.99) | (10.24) | (2.84) | (1.02) | (0.60) | |||||
| Capex | — | — | — | — | (0.67) | (0.45) | (0.20) | (0.01) | (0.07) | (0.05) | |||||
| Free cash flow | — | — | — | — | (0.76) | (9.43) | (10.43) | (2.85) | (1.09) | (0.65) | |||||
| Book value | — | — | — | — | (13.28) | 12.23 | (1.34) | (3.59) | (1.93) | 1.72 | |||||
| Shares, m | — | — | — | — | 2 | 5 | 8 | 8 | 11 | 18 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| P/S | — | — | — | — | 0.00 | 2.22 | 0.92 | 0.88 | 0.62 | 2.77 | |||||
| P/B | — | — | — | — | 20.50 | 3.06 | 0.00 | 0.00 | 0.00 | 15.38 | |||||
| EV/Sales | — | — | — | — | 0.00 | 1.19 | 1.00 | 0.87 | 0.51 | 2.51 | |||||
| EV/FCF | — | — | — | — | 0.00 | (2.12) | (0.84) | (1.98) | (3.32) | (22.58) | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | 0 | (41) | (81) | (24) | (11) | (11) | ||||
| Capex | — | — | — | — | (1) | (2) | (2) | 0 | (1) | (1) | |||||
| Free cash flow | — | — | — | — | (1) | (43) | (83) | (24) | (12) | (12) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | — | — | (10) | 67 | (15) | (5) | 10 | 38 | ||||
| Total debt | — | — | — | — | 22 | 17 | 15 | 15 | 12 | 13 | |||||
| Net debt | — | — | — | — | 5 | (79) | 4 | (1) | (9) | (28) | |||||
| Shareholders’ equity | — | — | — | — | (21) | 55 | (11) | (30) | (21) | 31 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | — | — | (52.45) | (79.60) | (80.08) | (73.35) | (36.77) | (61.94) | ||||
| ROIC | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (168.95) | |||||
| ROE | — | — | — | — | (8.25) | 1,118.80 | (356.12) | 155.68 | 51.18 | 781.68 | |||||
Negative figures in brackets.
Fiscal years to Dec 2025 · latest quarter Jun 2026
Charts ten years each
Owlet, Inc. vs peers in Medical Devices (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| RXST RxSight, Inc. | $194.2M | — (loss-making) | — (loss-making) | +0.31% (above 0%: growing) | n/m | −94.39% (below 0%: shrinking) | 76.72% | (40.81%) | Compare |
| INGN Inogen, Inc | $167.1M | — (loss-making) | — (loss-making) | +3.04% (above 0%: growing) | n/m | −51.15% (below 0%: shrinking) | 45.51% | (5.36%) | Compare |
| STIM Neuronetics, Inc. | $148.6M | — (loss-making) | — (loss-making) | +9.08% (above 0%: growing) | n/m | +62.06% (above 0%: growing) | 51.06% | (3.61%) | Compare |
| QTRX Quanterix Corporation | $145.2M | — (loss-making) | — (loss-making) | +34.44% (above 0%: growing) | n/m | +18.92% (above 0%: growing) | 38.52% | (150.22%) | Compare |
| MXCT MaxCyte, Inc. | $134.2M | — (loss-making) | — (loss-making) | −14.53% (below 0%: shrinking) | n/m | +54.74% (above 0%: growing) | 76.96% | (140.72%) | Compare |
| OWLT Owlet, Inc. | $129.8M | — (loss-making) | — (loss-making) | +29.94% (above 0%: growing) | n/m | +55.74% (above 0%: growing) | 64.44% | 5.14% | |
| APYX Apyx Medical Corporation | $107.8M | — (loss-making) | — (loss-making) | +22.08% (above 0%: growing) | n/m | −137.38% (below 0%: shrinking) | 63.89% | (13.01%) | Compare |
| LUCD Lucid Diagnostics Inc. | $105.7M | — (loss-making) | — (loss-making) | +26.74% (above 0%: growing) | n/m | −7.04% (below 0%: shrinking) | 1.97% | (868.45%) | Compare |
| ZOMDF Zomedica Corp. | $95.4M | — (loss-making) | — (loss-making) | +36.59% (above 0%: growing) | n/m | +40.48% (above 0%: growing) | 63.51% | (42.92%) | Compare |
| Median of peers | $139.7M | — | — | +15.58% | — | +5.94% | 57.29% | (41.86%) |
Owlet, Inc. (OWLT) key facts
- Owlet, Inc. (OWLT) is a Medical Devices company in the Healthcare sector, listed on the New York Stock Exchange.
- As of October 16, 2026, OWLT traded at $4.14, a market capitalization of $129.8 million.
- Return on equity was 781.7% and debt-to-equity 0.46.
- Its Piotroski F-score is 4 out of 9 and its Altman Z-score is −0.37 (distress zone) for fiscal 2025.
Owlet, Inc. (OWLT) Latest News
No news at this impact. Lower the threshold for more.